COMP <GO>
HALO vs EXEL // EV/EBITDA & P/E VALUATION
Halozyme Therapeutics Inc. (NASDAQ) VS. Exelixis Inc. (NASDAQ) • 15-METRIC TALLY: HALO 2
— EXEL 11
▲ EV/EBITDA & P/E VALUATION LEADER: EXEL
LAST: $130.91 (-0.21%) • MKT CAP: $14.89B
valuation
35.6x
LAST: $69.39 (+4.82%) • MKT CAP: $16.40B
valuation
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HALO VS. EXEL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HALO | EXEL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.60% | 96.00% | -12.40 | EXEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.00% | 35.10% | -17.10 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 35.6x | 18.4x | +17.20 | EXEL | /valuation <GO> |
| Free Cash Flow Yield | 4.33% | 5.34% | -1.01 | EXEL | /fcf-yield <GO> |
| Operating Margin | 33.60% | 37.60% | -4.00 | EXEL | /operating-margins <GO> |
| Net Profit Margin | 22.70% | 33.70% | -11.00 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 37.60% | 7.00% | +30.60 | HALO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.11 | 16.64 | -11.53 | EXEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | EXEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 79.0 | 63.3 | +15.70 | HALO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.96 | -0.08 | EXEL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.5x | 19.5x | +20.00 | EXEL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.89B | $16.40B | -$1.51B | EXEL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HALO REV | EXEL REV | HALO GROSS % | EXEL GROSS % | HALO FCF | EXEL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.40B | $2.32B | 83.6% | 96.4% | $644.6M | $875.8M |
| FY 2024 | $1.02B | $2.17B | 84.3% | 96.5% | $468.4M | $671.5M |
| FY 2023 | $829.3M | $1.83B | — | — | $351.3M | $251.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HALO // BETA 0.88
EXEL // BETA 0.96